Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these women. The Viennese company has begun a further clinical trial at the University of Graz with 20 patients that have received radiation after breast surgery. APN201 was developed by Polymun Scientific AG, another biotech company based in Vienna. Apeiron inlicensed the compound, which has already completed several clinical trials, the most advanced in Phase II. The human enyzme superoxide dismutase is essential for protecting human cells from damage by reactive oxygen species that are created through radiation.